Does the p38 MAP kinase inhibitor pamapimod have potential for the treatment of rheumatoid arthritis?

Expert Opinion on Pharmacotherapy

Volumn 11, Issue 14, 2010, Pages 2437-2442

  Doggrell, Sheila A ^a   Christensen, Anne Marie ^a  

^a QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

Author keywords

Clinical trials; Methotrexate; P38 inhibition; Pamapimod; Pharmacokinetics; Rheumatoid arthritis

Indexed keywords

ALANINE AMINOTRANSFERASE; CREATINE KINASE; METHOTREXATE; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; PAMAPIMOD; UNCLASSIFIED DRUG;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL TRIAL; CREATINE KINASE BLOOD LEVEL; DIZZINESS; DRUG DOSAGE FORM COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG WITHDRAWAL; FOLLICULITIS; GASTROINTESTINAL DISEASE; HEADACHE; HUMAN; LOW DRUG DOSE; NEUROLOGIC DISEASE; NOTE; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; SKIN DISEASE; TREATMENT RESPONSE; URINARY TRACT INFECTION;

EID: 77956607528     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2010.507631     Document Type: Note

References (11)

1. Available from: http://emedicine. medscape.com/article/331715-print Smith HR. Rheumatoid arthritis [Accessed 28th April 2010]
2. Schindler JF, Monahan JB, Smith WG. p38 pathway kinases as anti-inflammatory drug targets. J Dent Res 2007;86:800-811
3. Hill RJ, Dabbagh K, Phippard D, et al. Pamapimod, a novel p38 mitogen-activated protein kinase inhibitor: preclinical analysis of efficacy and selectivity. J Pharmacol Exp Ther 2008;327:610-619
4. Cohen SB, Cheng TT, Chindalore V, et al. Evaluation of the efficacy and safety of pamapimod, a p38 MAP kinase inhibitor, in a double-blind, methotrexate-controlled study of patients with active rheumatoid arthritis. Arthritis Rheum 2009;60:335-344
5. Zhang X, Huang Y, Navarro M, et al. A proof-of-concept and drug-drug interaction of pamapimod, a novel p38 MAP kinase inhibitor, with methotrexate in patients with rheumatoid arthritis. J Clin Pharmacol 2010. [Epub ahead of print]
6. Alten RE, Zerbini C, Jeka S, et al. Efficacy and safety of pamapimod in patients with active rheumatoid arthritis receiving stable methotrexate therapy. Ann Rheum Dis 2010;69:364-367
7. Damjanow N, Kauffman RS, Spencer-Green GT. Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MARK inhibitor, in rheumatoid arthritis: results of two randomized, double-blind, placebo-controlled clinical studies. Arthritis Rheum 2009;60:1232-1241
8. Wada Y, Nakajima-Yamada T, Yamada K, et al. R-130823, a novel inhibitor of p38 MAPK, ameliorates hyperalgesia and swelling in arthritis models. Eur J Pharmacol 2005;506:285-295
9. Almeida AP, Bayer BM, Horakova Z, Beaven MA. Influence of indomethacin and other anti-inflammatory drugs on mobilization and production of neutrophils: studies with carrageenan-induced inflammation in rats. J Pharmacol Exp Ther 1980;214:74-79
10. Chopa P, Kulkarni O, Gupta S, et al. Pharmacological profile of AW-814141, a novel, potent, selective and orally active inhibitor of p38 MAP kinase. Int Immunopharmacol 2010;10:467-473
11. Schreiber S, Feagan B, D'Haens G, et al. Oral p38 mitogen-activated protein kinase inhibition with BIRB 796 for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol 2006;4:325-334